Daikaffil Chemicals India Limited has submitted a regulatory filing to BSE Limited regarding an upcoming Board of Directors meeting scheduled for Tuesday, July 14, 2026.
The primary agenda items for the board meeting include:
1. Consideration and approval of Revised Financial Results for the quarter and year ended March 31, 2026, together with the Statutory Auditors' Report thereon. The revision is specifically limited to the incorporation of the Consolidated Cash Flow Statement.
2. Presentation to the Board of a notice received from BSE Limited regarding the company's non-submission of the Consolidated Cash Flow Statement, in terms of SEBI Standard Operating Procedure (SOP) guidelines, for their review and comments.
The filing confirms that the trading window for dealing in the company's securities is already closed for all designated persons and their immediate relatives, in accordance with the provisions of the SEBI (Prohibition of Insider Trading) Regulations.